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Persons with limited life expectancy (LLE) – less than 1 year – are significant consumers of health care, are
at increased risk of polypharmacy and adverse drug events, and have dynamic health statuses. Therefore,
medication use among this population must be appropriate and regularly evaluated. The objective of this
review is to assess the current state of knowledge and clinical practice presented in the literature
regarding preventive medication use among persons with LLE. We searched Medline, Embase, and
CINAHL using Medical Subject Headings. Broad searches were first conducted using the terms ‘terminal
care or therapy’ or ‘advanced disease’ and ‘polypharmacy’ or ‘inappropriate medication’ or ‘preventive
medicine’, followed by more specific searches using the terms ‘statins’ or ‘anti-hypertensives’ or
‘bisphosphonates’ or ‘laxatives’ and ‘terminal care’. Frameworks to assess appropriate versus
inappropriate medications for persons with LLE, and the prevalence of potentially inappropriate
medication use among this population, are presented. A considerable proportion of individuals with a
known terminal condition continue to take chronic disease preventive medications until death despite
questionable benefit. The addition of palliative preventive medications is advised. There is an indication
that as death approaches the shift from a curative to palliative goal of care translates into a shift in
medication use. This literature review is a first step towards improving medication use and decreasing
polypharmacy in persons at the end of life. There is a need to develop consensus criteria to assess
appropriate versus inappropriate medication use, specifically for individuals at the end of life.
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Introduction
Persons with limited life expectancy (LLE) – less than
1 year – are at increased risk of polypharmacy and
adverse drug events, have complex and dynamic
health statuses, and have unique health-care needs
due to their LLE.
1,2 Therefore, it is imperative that
medication use among this population be appropriate
and regularly evaluated.
Persons with LLE have an increased risk of poly-
pharmacy, i.e. taking five or more medications,
because they are commonly receiving medications to
control their terminal disease and to manage pain
and symptoms, as well as receiving medications for
long-term prevention and management of chronic con-
ditions.
3 Polypharmacy is associated with a greater
risk of adverse drug events because of drug–drug
interactions and drug–disease interactions.
3–5
The objective of this paper is to report on the
current knowledge from the literature regarding pre-
ventive medication use among persons with LLE.
This review begins by examining criteria and frame-
works for assessing appropriate versus inappropriate
medication use among persons with LLE. The litera-
ture that examines appropriate versus inappropriate
medication use among this population is then pre-
sented. Lastly, we highlight the importance of evaluat-
ing the continuance in the use of long-term chronic
disease preventive medications and the addition of
palliative preventive medications for persons with LLE.
For the purpose of this paper, preventive medi-
cations are defined as drugs that are used to proac-
tively manage a disease or symptom. There is an
implicit assumption, which is not fully achievable in
practice, that it is possible to prognosticate that a
person has an LLE, and therefore adjust medication
use accordingly.
6 This paper is not a full systematic
literature review, but rather is bounded to raise aware-
ness and frame the issues. A comprehensive review of
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15the extensive literature on palliative medication use is
beyond the scope of this article. This literature
review provides a useful and substantive base for
future investigation into the use of preventive medi-
cations at end of life.
Methods
A Medline, Embase, and Cumulative Index to
Nursing and Allied Health Literature (CINAHL)
search using the terms ‘preventive medication’ and
‘terminal care’ or ‘palliative care’ retrieved no articles.
Therefore, we expanded the search to include the terms
‘terminal care or therapy’ or ‘palliative care or
therapy’ or ‘advanced disease’ and ‘polypharmacy’
or ‘inappropriate medication’ or ‘preventive medicine’
and retrieved 341 papers. Most studies of medication
use for persons with LLE focus on a specific medi-
cation, rather than preventive medications in general,
or a specific outcome rather than a spectrum of
events at end of life. Therefore, we conducted an
additional search using the terms ‘statins’ or ‘anti-
hypertensives’ or ‘bisphosphonates’ or ‘laxatives’ and
‘terminal care’ and retrieved an additional 23 articles.
We then applied ISI Web of Knowledge’s ‘cited refer-
ence’ facility to all included articles and hand-searched
reference lists and identified a further 6 studies, giving
a total of 370 potentially relevant papers.
Each search was limited to studies published in
English and was unrestricted by year of publication.
Based on the abstracts, two of the authors (AM, JF)
independently reviewed the citations and discussed
differences on inclusion of articles into this review of
appropriate versus inappropriate use of preventive
medications among persons with LLE. The literature
search process is summarized in Fig. 1.
Results
Frameworks and guidelines to identify
appropriate versus inappropriate medications
Several criteria or indices have been developed to clas-
sify appropriate versus inappropriate medications
for the elderly including the Beers criteria (or Beers
list), the Medication Appropriateness Index, and the
Screening Tool of Older Persons’ Potentially
Inappropriate Prescriptions (STOPP) criteria.
7–9 A
limitation of the Beers criteria and these other frame-
works is that they are developed specifically for elderly
populations, who are onlya subset of persons at end of
life.
2 Individuals at the end of life are not all elderly
and have varied and dynamic health conditions that
Figure 1 Process to identify relevant literature.
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sive, medication appropriateness index or criterion.
A diagnosis of LLE modifies the goals of care
towards a more palliative and supportive focus, and
subsequently alters the medications that are appropri-
ate or inappropriate.
10
The literature search identified three papers that
address the issue of developing specific frameworks
or guidelines for identifying appropriate versus inap-
propriate medication use among persons with
LLE.
2,10,11 Of these three articles, two (Holmes et al.
and Bain and Weschules) present specific guidelines
or frameworks for assessing appropriate medication
use at end of life. The remaining paper
11 is a letter to
the editor that highlights the need to address this issue.
Bain and Weschules
10 examined the feasibility of
applying the Beers criteria to medication use among
older adults receiving hospice care. They developed a
list of potentially inappropriate medications based on
the Beers criteria and The Hospice Pharmacia
Medication Use Guidelines™ seventh edition. The
latter is a set of proprietary pharmacotherapy-based
guidelines and algorithms specific to hospice care
designed as a clinical tool for the pharmacological
management of symptoms common at end of life.
12
Twenty-four members of a multidisciplinary panel
reviewed the list and assessed the appropriateness
of each medication or medication class for hospice
patients aged 65 and older. The panelists considered
some medications, e.g. propoxyphene, to be inap-
propriate for all patients; however, some medications,
e.g. lorazepam and haloperidol, which were otherwise
considered inappropriate according to the Beers cri-
teria, were judged to be appropriate for hospice care.
The authors note the need to develop potentially
inappropriate medication criteria that are specific to
hospice care.
Holmes and colleagues designed a medications
model that is specific to persons with LLE.
2 This
model incorporates individuals’ remaining life expect-
ancy, goals of care, and time until benefit of medi-
cations.
2 The Holmes et al. prescribing model is less
explicit than the Beers criteria and is meant to assist
health-care providers in making decisions regarding
medication use for persons at the end of life. The
Holmes et al. prescribing model does not provide
specific guidelines regarding appropriate versus inap-
propriate medications, but does provide a framework
to direct prescribing to avoid inappropriate or ineffec-
tive medication use.
Prevalence of potentially inappropriate
medication use at end of life
Although there is literature examining potentially
inappropriate use of medications among the
elderly,
13–17 few studies focus specificallyon preventive
medications and persons with LLE. Our search
retrieved only 11 studies, summarized in Table 1,
which focus on the appropriateness of medication
use among persons with LLE.
17–27
A considerable number of individuals with LLE
continue to receive potentially inappropriate medi-
cations, yet results vary by study location and popu-
lation. Fahlman et al.
17 retrospectively applied the
Beers criteria to examine the extent of inappropriate
medication use among 4602 community-dwelling indi-
viduals in the last year of life in the USA. They ident-
ified that 44% of participants received at least one
potentially inappropriate medication in their last
year of life.
17 In contrast, Nicholson et al.
23 identified
that 25% of individuals admitted to a hospice in
England were taking futile or unnecessary medications
according to the admitting physicians.
In order to assess the changes in potentially inap-
propriate medication use, Currow et al.
19 examined
medication use each month from palliative care refer-
ral until death. They identified that the total numberof
medications taken increased as death approached due
to a greater number of symptom-specific medications,
while medications for chronic diseases decreased.
Moreover, two studies analyzed the impact of a
palliative care consultation on medication use.
Without distinguishing between appropriate and inap-
propriate medications, Koh and Koo
22 identified that
the total number of medications taken prior to and
after palliative care assessments in Singapore remained
unchanged. Suhrie et al.
26 applied the Medication
Appropriateness Index
8 to examine medication use
by 89 individuals before and after admission to a pal-
liative care unit in Pittsburg, PA. For the purpose of
their study, unnecessary medications were defined as
those that lacked indication (e.g. prescribing iron for
an individual without an iron deficiency), lacked effec-
tiveness (e.g. prescribing a drug that has greater side
effects than an alternative drug), or were duplicate
medication. They identified that the use of unnecess-
ary medications declined from a mean of 1.7 to 0.6
medications per person after admission to the pallia-
tive care unit.
26
To more precisely report on the appropriateness of
medication use, selected studies restricted their analysis
toa specific conditionorspecific preventive medication.
Theliteraturesearchretrievedfourstudiesthatexamined
specific conditions: advanced dementia
18,21 and term-
inal cancer.
20,24 Holmes et al.
21 examined medication
use in 34 persons with advanced dementia who were
registered in a palliative care program and assessed
appropriatenessusingaDelphipanelof13geriatricians.
Twenty-nine percent of persons were receiving a
medication that was classified as never appropriate,
including HMG-CoA (3–hydroxy–3–methyl–glutaryl
coenzyme A) reductase inhibitors (statins),
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grel, and 21% were receiving medication that were
rarely appropriate.
21 Blass et al.
18 examined
medication use among nursing home residents with
advanced dementia (n=125), in particular how
medication use changed as death approached. While
the total number of medications prescribed did not
vary, the use of opioid analgesics increased, while
the use of most other medications decreased, e.g.
for cardiovascular disease and dementia.
18 While the
study did not determine the appropriateness of the
medications, the high rates of medication use are
of concern.
Riechelmann et al.
24 retrospectively examined 372
persons with advanced/incurable malignancies who
were registered with a palliative care program. The
study identified that 22% of individuals were receiving
at least one unnecessary or duplicate medication.
Fifty-six percent of unnecessary medications were
statins and 88% of duplicate medications were benzo-
diazepines.
24 In comparison, Fede et al.
20 reported
that 24% of individuals with advanced cancer in Sao
Paulo, Brazil, were receiving unnecessary medication
according to the admitting physician.
Two studies (Silveira et al.
25 and Tanvetyanon and
Choudhury
27) focused on statin use in persons with
Table 1 Studies examining prevalence of unnecessary and inappropriate medication use among individuals with LLE
Study Study location Population Outcomes Criteria/index
Blass et al.
(2008)
18
Baltimore,
Maryland, USA
125 nursing home
residents with
advanced dementia
Total number and type of
prescribed medications
at baseline, with changes
prior to death
Medications were not assessed
as appropriate versus
inappropriate
88 patients died within
6-month study period
Currow et al.
(2007)
19
Adelaide, South
Australia
260 patients referred to
palliative care
programs
Medication use from
palliative care referral
to death
Medications classified as either
for co-morbid conditions or
for symptom control using the
Beers’ consensus criteria
Fahlman et al.
(2007)
17
USA 4602 community elderly
(>65) from a
managed care
organization
Use of potentially
inappropriate
medications during
last year of life
Beers consensus criteria
Fede et al.
(2010)
20
Sao Paulo, Brazil 87 patients with
advanced cancer
Use of unnecessary
medications
Unnecessary medications
determined by authors
through a literature search
and expert consensus
Holmes et al.
(2008)
21
Illinois, USA 34 community and long-
term care residents
with advanced
dementia
Appropriate versus
inappropriate medication
used by individuals with
advanced dementia
Appropriate versus
inappropriate determined
by panel of 12 geriatricians;
classified as never, rarely,
sometimes, or always
appropriate, or no consensus
Koh and Koo
(2002)
22
Singapore 345 patients in an
in-patient palliative
care program, in-
patient hospice
program, or receiving
home care service
Number of medications
taken prior to and after a
palliative care referral
Futility or appropriateness not
assessed
Nicholson et al.
(2001)
23
England 106 patients admitted to
St Benedict’s Hospice
Number of futile or
inappropriate
medications when
admitted
Futility and inappropriateness
assessed by physician
Riechelmann
et al. (2009)
24
Toronto, ON,
Canada
372 patients with
advanced cancer
receiving care in
palliative care clinics
Proportion taking futile
medications
Futility of medications
determined by authors;
classified as duplicates
or unnecessary
Silveira et al.
(2008)
25
Central Illinois,
Indiana,
Michigan, and
Northwest Ohio,
USA
337 cases with LLE
versus 1247 controls
without LLE; LLE
identified using
Palliative Care Index
diagnoses
Prevalence of statin use
during last 6 months
of life; variations by
presence or absence
of LLE
Futility or appropriateness
not assessed
Suhrie et al.
(2009)
26
Pittsburgh,
Pennsylvania,
USA
89 patients who died in
a geriatric palliative
care unit
Unnecessary medication
use at first admission and
in last 30 days before
death from pharmacist
drug review
Assessed using unnecessary
drug use measure, a
classification of Medication
Appropriateness Index
Tanvetyanon and
Choudhury
(2006)
27
Chicago, Illinois,
USA
47 patients with
advanced lung cancer
receiving statins at
diagnosis
Discontinuation of statins
by timing and
characteristics of
discontinuation
Futility or appropriateness not
assessed
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25 used a matched case–control
study design to examine whether individuals with a
recognizable life-limiting condition would have
statins discontinued more often and more quickly
than a control group. They compared statin discon-
tinuation among persons with a recognizable life-limit-
ing condition, as defined by the Veterans Health
Administration Palliative Care Diagnoses Index, to
those who died of other causes, matched on age,
sex, co-morbid conditions, and socioeconomic status.
Silveira et al.
25 identified that 51% of cases and 64%
of controls received statins until death. There was no
statistically significant difference in the timing of
discontinuation between cases and controls.
Tanvetyanon and Choudhury
27 examined patterns of
statin discontinuation among 47 persons who were
diagnosed with stage IIIb or IV lung cancer and
were taking statins at the time of diagnosis. Eighty-
nine percent of persons received at least one prescrip-
tion renewal after diagnosis. Statins were eventually
discontinued in 53%. The median time of discontinu-
ation was approximately 250 days after diagnosis.
27
The 11 studies examining appropriate versus inap-
propriate medication use among persons with LLE
suggest that a considerable proportion of individuals
at the end of life continue to take chronic disease pre-
vention medications and other potentially inappropri-
ate or unnecessary medications. However, there is an
indication that as death approaches the shift from
curative to palliative goals of care translates into
some change in medication use. Beyond these 11
studies that report on the prevalence of unnecessary
and inappropriate medication at end of life, two
additional papers focus on discontinuing preventive
chronic disease medications, and a further six on
adding palliative preventive medications.
Eliminating chronic disease preventive
medications of diminishing value
The literature search identified only two papers with
a specific focus on discontinuing chronic disease pre-
ventive medications among persons with LLE.
1,3
Individuals in the general population are prescribed
long-term medications such as statins to control
cholesterol levels, anti-hypertensives to control blood
pressure, and bisphosphonates to maintain bone
density. However, if a person is diagnosed with a term-
inal disease, the benefit of these long-term preventive
medications may become negligible, and the potential
for harm may outweigh the benefit.
28 The safety, effi-
cacy, and benefits of statins, anti-hypertensives, and
bisphosphonates have been demonstrated for the
general population through several randomized
control trials;
29–31 however, there is limited evidence
of their appropriateness among persons with LLE, in
part because persons with LLE are rarely included in
clinical trials.
3 There are changes in pharmacody-
namics and pharmacokinetics caused by terminal dis-
eases, which result in medications reacting differently
than expected. This leads to potentially greater risk
of adverse effects and possible reduction of benefit.
28
Time until benefit – the period of time required for a
medication to be of value to a person – of preventive
medications must also be considered, as it may
extend beyond life expectancy. Therefore, there is a
need to evaluate prescribing for persons with LLE
and to consider discontinuing medications that are
no longer beneficial.
2 The use of statins is a case in
point.
Statins are prescribed for the primary prevention –
prior to disease occurrence – and tertiary prevention –
minimizing effects of a disease that is present and
avoiding re-occurrence – of cardiovascular
disease.
29–31 If the goal of care is palliative, long-term
prevention of cardiovascular disease is potentially
unnecessary, may contribute to polypharmacy, and
is an additional cost to the person and/or health
system.
3 Lastly, persons suffering from advanced
disease usually have a natural decrease in cholesterol
level through weight loss and studies have shown
increased risk of adverse effects from statins among
persons with LLE.
32,33
In addition to the increased risk of polypharmacy
and thus possible adverse events, preventive medi-
cation use by persons with LLE has psychological
and financial considerations.
1 If a preventive medi-
cation is discontinued in an individual with LLE,
they may feel that the health-care providers are
giving up hope. In contrast, renewing a person’s
preventive medication may provide false hope.
Therefore, continuation or discontinuation of a pre-
ventive medication should be clearly discussed with
the individual before being put into practice.
1
In summary, the use of chronic medications that
reduce the risk of the occurrence or exacerbation of
disease many years in the future should be reconsid-
ered for persons whose life expectancy is limited.
However, the introduction of new medications that
prevent or reduce the risk of disease- or treatment-
related adverse events may be indicated. This shift is
illustrated in Fig. 2.
Adding palliative preventive medications
The search strategy identified six papers that specifi-
cally address the issue of adding medications to the
treatment regimen at end of life to avoid anticipated
adverse outcomes.
34–39 For example, it is known that
bisphosphonates may prevent bone loss associated
with androgen-deprivation therapy for prostate
cancer and metastases to the bone from breast
cancer.
34 Beyond a disease-specific preventive focus,
symptom-specific preventive medications can also be
Maddison et al. Preventive medication use among persons with LLE
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pating effects of opioid painkillers is a case in point.
35
Constipation is one of the most common symptoms
experienced by persons with LLE.
36 Constipation
causes abdominal pain, cramping, and nausea and
vomiting, and results in substantial declines in
quality of life. The prevalence of constipation among
patients receiving palliative care has been reported to
be as high as 87%.
35 Numerous factors contribute to
the high prevalence of constipation among persons
with LLE, in particular the use of opioids, dehy-
dration, inactivity, difficulty eating, and specific
disease-related effects.
35,36 It is clinically rec-
ommended that laxatives be prescribed concurrently
with a strong opioid in order to prevent opioid-
induced constipation.
35–37 Bouvy et al.
38 examined
concurrent laxative and strong opioid use among
269 elderly persons throughout the Netherlands.
They identified that only 37% of these individuals
were prescribed a laxative within 5 days of starting a
strong opioid. However, Goodman et al.
39 examined
laxative use specifically among persons who were
admitted to 1 of 11 hospices in the UK and found
that 74% received laxatives with strong opioids.
Recommendations and conclusion
Medication use should be regularly monitored and
evaluated throughout a person’s lifetime. However,
when a person is diagnosed with an LLE condition, it
is vitally important to reassess medication use to align
with the goals of care and life expectancy. Although
timing and medication use vary from person to
person, the shift in goals of care as death approaches
should be accompanied by ongoing evaluation of and
appropriate changes in preventive medication use.
The literature examining the appropriate use of
long-term preventive medications among persons
with LLE contains several gaps, which should be
addressed. Notably, there is minimal consensus in
how best to assess medication use at end of life and
varied definitions of inappropriate and futile medi-
cations. To date, there is limited research that reports
whether ineffective or inappropriate preventive medi-
cations are being discontinued and whether appro-
priate palliative preventive medications are being
initiated. Evidence of the discontinuation of poten-
tially inappropriate preventive medication is limited
mostly to descriptive or pilot studies and specific
forms of potential appropriate/inappropriate use of
preventive medications. In order to improve medi-
cation use, decrease polypharmacy and adverse drug
events, reduce preventable adverse end-of-life events,
and optimize medication costs, the first step is to
develop a consensus framework or criterion to evalu-
ate medication use at end of life, then to identify
current patterns of use among persons with LLE.
Inclusion of the key word(s) ‘preventive medication’
and ‘terminal care’ in papers on medications for
persons with LLE would enable future literature
searches.
In the meantime, health-care providers can promote
optimal medication use among persons with LLE
by regularly and critically evaluating the medication
regimens of their patients within this population to
assess the appropriateness of the continued use of pre-
ventive medications. The Holmes et al.
2 prescribing
model may provide a useful framework for this evalu-
ation. Further, decisions to initiate, continue, or dis-
continue preventive medications at end of life should
be preceded by meaningful dialogue and communi-
cation with the person with LLE.
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Figure 2 Conceptualizing the transition in medication use at end of life. (A) Goal of care begins to transition towards palliative
and supportive care. (B) Goal of care is solely supportive and palliative. All long-term preventive medications and disease-
modifying medications discontinued.
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